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Sir,
We acknowledge the discussion points raised by Scho ¨ffski et al
(2010), both in their letter and in their prospective evaluation of
sunitinib-induced hypothyroidism published in this journal in
2008 (Wolter et al, 2008).
We reported on a small, open-label, phase II clinical trial of
sunitinib on a continuous daily dosing schedule in patients with
advanced NSCLC and, as noted in the discussion section of the
paper, the primary end point of this trial (the reporting of at least
five objective responses) was not reached. However, despite the
low overall response rate, we were encouraged by the time-to-event
results obtained, which we feel are concordant with a signal of
activity and with time-to-event data observed on Schedule 4/2
(4 weeks on treatment followed by 2 weeks off; Socinski et al,
2008). Furthermore, as this was not a phase III trial designed to
definitively assess the activity of sunitinib in patients with lung
cancer, we feel justified in reporting intriguing observations
pertaining to antitumour activity. Conclusive efficacy statements
cannot, and have not, been made in this paper and we believe that
the interpretation of the trial data was suitably guarded.
Scho ¨ffski et al also suggest correlations between the effect of
sunitinib on thyroid function and the incidence of fatigue in our
trial. There were few data to support such a correlation at the time
our trial was designed; consequently, thyroid function measure-
ment was not part of the clinical protocol. Nevertheless, we
acknowledge that 53–85% of oncology patients treated with
sunitinib develop thyroid test abnormalities, and a substantial
percentage develop clinical manifestations of thyroid dysfunction
(Desai et al, 2006; Rini et al, 2007). Guidance for the use of
sunitinib in its licensed indications is available and recommends
baseline laboratory measurement of thyroid function, with hyper-
and hypothyroidism treated as per standard medical practice.
Studies investigating the impact of sunitinib therapy on thyroid
function are ongoing.
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